TMS Co., Ltd. (JP:4891)
:4891
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥120.00 - ¥185.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)256.91K
Market Cap
¥6.41B
Enterprise Value¥3.33B
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,485,767
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)2.94
Price to Sales (P/S)0.00
P/FCF Ratio-15.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Debt / Conservative Balance SheetA debt-free balance sheet materially lowers solvency risk and provides financing flexibility. For a clinical-stage biotech burning cash, absence of leverage preserves optionality for R&D spending, partnership deals or opportunistic funding without debt-servicing constraints.
Solid Liquidity & Equity BaseNear-term liquidity (¥2.78B cash) and high equity ratio give the company runway to execute trials and advance programs without immediate dilution. Robust net assets and recent ¥640M financing inflows reduce short-term funding pressure and support clinical development cadence.
Pipeline Milestone: Phase II/III EnrollmentEntry into a global Phase II/III trial is a structural inflection point: a successful ORION study would validate the drug's extended treatment window, support regulatory filings and materially expand addressable market, creating sustainable commercial opportunity and partner interest.
Bears Say
Sustained Losses & Declining EquityMulti-year operating and net losses with equity erosion (equity down from ~¥3.71B to ~¥2.82B) indicate the company is consuming capital rather than generating returns. Persisting negative ROE (-23% in 2025) undermines internal funding capacity and heightens reliance on external financing.
Persistent Cash BurnSustained negative operating and free cash flow signals ongoing cash consumption to fund operations and trials. Even though burn eased versus prior years, continued deficits mean management must secure additional capital or reduce spend, which can delay programs or dilute shareholders over the medium term.
Volatile Revenue & Earnings VisibilityThe abrupt transition from profitable 2022 to repeated losses and intermittent revenue undermines predictability. Management withheld 2026 guidance, reflecting uncertain near-term cash generation and making long-term planning and partner/customer confidence dependent on binary clinical outcomes.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥120.00 and its highest was ¥185.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥6.41B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Jul 10, 2026 which is in 98 days.
How were TMS Co., Ltd.’s earnings last quarter?
Currently, no data Available
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 45,485,767 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company has a collaboration with Hokkaido University and Kanazawa University to evaluate the potential of the drug candidate compounds as novel drugs, as well as a joint research agreement with Teikyo University to identify biomarkers for renal function and a strategic alliance with Ji Xing Pharmaceuticals Limited. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.